Year End 2004 Earnings

Twelve Months Ended
Total Revenue
Net Income (loss)


Weighted Average Number of Shares Outstanding
Equivalent Share

New York, NY- April 15, 2005 - Daxor Corporation, (AMEX: DXR) a leading medical instrumentation and biotechnology company, today announced the Company had an increase in expenses and operating revenues. The Company had a loss of 12 cents per share in 2004. This was due to an anticipated increase in expenses as the Company expanded its sales and marketing staff in 2004. Operating revenues from the BVA-100 division, however, increased by 20% in 2004. The Company intends to continue to expand its sales staff as well as increase its presence at trade shows. In the past 3 years, there have been research papers from major medical institutions concerning the benefits of measuring blood volume. The Company produces the BVA-100, the only semi-automated Blood Volume Analyzer approved by the FDA.

On February 23, 2005 , the Company was informed that its auditors of the past 25 years were not PCAOB registered in accordance with Sarbanes-Oxley. The Company, therefore, retained the services of Rotenberg Meril Solomon Bertiger & Guttilla, P.C. As part of the change in auditors, a repeat audit of the 2003 filings was required. That audit, and 10K, has been completed, with no material change, and submitted. The 2004 10K submission will be filed no later than Tuesday, April 19, 2005 .


For more infomation, please contact:
Richard Dunn
Director of Operations
Diane Meegan
Investor Relations